The Treatment of Human African Trypanosomiasis

Advances in Parasitology

Volumn 33, Issue C, 1994, Pages 1-47

  Pepin J ^a   Milord, F ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b Direction générale de la santé publlque de la Monteregle ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; DIMINAZENE; DIMINAZENE ACETURATE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; PENTAMIDINE ISETHIONATE; SURAMIN;

BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN INJURY; CONVULSION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; FEVER; HUMAN; HYPOGLYCEMIA; HYPOTENSION; NEUROLOGIC DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS;

TRYPANOSOMA; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 0028366196     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-308X(08)60410-8     Document Type: Chapter

References (179)

1. Abaru, D.E., Matovu, F.S., Berenil in the treatment of early stage human trypanosomiasis cases. Bulletin Trimestriel d'Information sur les Glossines et les Trypanosomiases 7 (1984), 150–151.
2. Abaru, D.E., Liwo, D.A., Isakina, D., Okori, E.E., Retrospective long-term study of effects of Berenil by follow-up of patients treated since 1965. Tropical Medicine and Parasitology 35 (1984), 148–150.
3. Adams, J.H., Haller, L., Boa, F.Y., Doua, F., Dago, A., Konian, K., Human African trypanosomiasis (T. b. gambiense) a study of 16 fatal cases of sleeping sickness with some observations on acute reactive encephalopathy. Neuro- pathology and Applied Neurobiology 12 (1986), 81–94.
4. Adriaenssens, K., Nota over de toxiciteit van Mel B in Trypanosoma rhodesiense slaapziekte. Annales de la Société Beige de Médecine Tropicale 40 (1960), 701–704.
5. Adriaenssens, K., Furaltadone in the treatment of Rhodesian sleeping sickness. Tropical and Geographical Medicine 14 (1962), 171–182.
6. Adriaenssens, K., Preliminary report of Rhodesian sleeping sickness treated with NF-902 (a levo-isomer of furaltadone). Annales de la Société Beige de Mtdecine Tropicale 42 (1962), 31–38.
7. Aliu, Y.O., Odegaard, S., Pharmacokinetics of diminazene in sheep. Journal of Pharmacokinetics and Biopharmaceutics 13 (1985), 173–184.
8. Andrade, S.G., Magalhaes, J.B., Pontes, A.L., Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bulletin of the World Health Organization 63 (1985), 721–726.
9. Anika, S.M., Onyeyili, P.A., Effects of trypanosomal infection on the Pharmacokinetics of diminazene aceturate in dogs. Tropical Medicine and Parasitology 40 (1989), 419–421.
10. Apted, F.I.C., The treatment of advanced cases of Rhodesian sleeping sickness by Mel B and Arsobal. Transactions of the Royal Society of Tropical Medicine and Hygiene 47 (1953), 387–398.
11. Apted, F.I.C., Four years experience of melarsen oxide/BAL in the treatment of late-stage Rhodesian sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 51 (1957), 75–86.
12. Apted, F.I.C., Nitrofurazone in the treatment of sleeping sickness due to Trypanosoma rhodesiense. Transactions of the Royal Society of Tropical Medicine and Hygiene 54 (1960), 225–228.
13. Apted, F.I.C., Treatment of human trypanosomiasis. Mulligan, H.W., Potts, W.H., (eds.) The African Trypanosomiases, 1970, George Allen and Unwin, London, 684–710.
14. Apted, F.I.C., The epidemiology of Rhodesian sleeping sickness. Mulligan, H.W., Potts, W.H., (eds.) The African Trypanosomiases, 1970, George Allen and Unwin, London, 645–660.
15. Apted, F.I.C., Clinical manifestations and diagnosis of sleeping sickness. Mulligan, H.W., Potts, W.H., (eds.) The African Trypanosomiases, 1970, George Allen and Unwin, London, 661–683.
16. Apted, F.I.C., Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the eastern hemisphere. Pharmacology and Therapeutics 11 (1980), 391–413.
17. Bacchi, C.J., Nathan, H.C., Hutner, S.H., McCann, P.P., Sjoerdsma, A., Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210 (1980), 332–334.
18. Bacchi, C.J., Nathan, H.C., Clarkson, A.B., Bienen, E.J., Bitonti, A.J., McCann, P.P., Sjoerdsma, A., Effect of ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. American Journal of Tropical Medicine and Hygiene 36 (1987), 46–52.
19. Bacchi, C.J., Nathan, H.C., Livingston, T., Valladares, G., Saric, M., Sayer, P.O., Njogu, A.R., Clarkson, A.B., Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrobial Agents and Chemotherapy 34 (1990), 1183–1188.
20. Bailey, N.M., Oral Berenil in the treatment and prophylaxis of human trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 62, 1968, 122.
21. Bales, J.D., Harrison, S.M., Mbwabi, D.L., Schechter, P.J., Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Annals of Tropical Medicine and Parasitology 83:supplement 1 (1989), 111–114.
22. Bertrand, E., Rive, J., Série, F., Koné, I., Encéphalopathie arsénicale et traitement de la trypanosomiase. Médecine Tropicale 33 (1973), 385–390.
23. Bitonti, A.J., Dumont, J.A., McCann, P.P., Characterization of Trypanosoma brucei brucei 5-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochemical Journal 237 (1986), 518–521.
24. Bitonti, A.J., McCann, P.P., Sjoerdsma, A., Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoro-methylornithine. Biochemical Pharmacology 35 (1986), 331–334.
25. Bitonti, A.J., Byers, T.L., Bush, T.L., Casara, P.J., Bacchi, C.J., Clarkson, A.B., McCann, P.P., Sjoerdsma, A., Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase. Antimicrobial Agents and Chemotherapy 34 (1990), 1485–1490.
26. Bouteille, B., Darde, M.L., Pestre-Alexandra, M., Dumas, M., Breton, J.C., Nicolas, J.A., Catanzano, G., Munoz, M., Traitement de la trypanosomiase expérimentale du mouton àTrypanosoma brucei brucei recherche d'une dose minima active de mélarsoprol. Bulletin de la Société de Pathologie Exotique et de ses Filiales 81 (1988), 548–554.
27. Brabin, L., Brabin, B.J., Parasitic infections in women and their consequences. Advances in Parasitology 31 (1992), 1–81.
28. Brener, Z., Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western hemisphere. Pharmacology and Therapeutics 7 (1979), 71–90.
29. Bronner, U., Doua, F., Ericsson, O., Gustafsson, L.L., Miézan, T.W., Rais, M., Rombo, L., Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Cote d'lvoire. Transactions of the Royal Society of Tropical Medicine and Hygiene 85 (1991), 608–611.
30. Buyst, H., The treatment of T. rhodesiense sleeping sickness with special reference to its physio-pathological and epidemiological basis. Annales de la Société Beige de Médecine Tropicale 55 (1975), 95–104.
31. Byers, T.L., Bush, T.L., McCann, P.P., Bitonti, A.J., Antitrypanosomal effects of polyamine biosynthesis inhibitors correlate with increases in Trypanosoma brucei brucei S-adenosyl-L-methionine. Biochemical Journal 274 (1991), 527–533.
32. Call, R.A., Gunn, F.D., Arsenical encephalopathy. Report of a case. Archives of Pathology 49 (1949), 119–128.
33. Castro, J.A., Diaz de Toranzo, E.G., Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas* disease). Biomedical and Environmental Sciences 1 (1988), 19–33.
34. Cattand, P., Miezan, B.T., De Raadt, P., Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bulletin of the World Health Organization 66 (1988), 83–86.
35. Ceccaldi, J., Du traitement des nouveaux trypanosés par le 3854 RP ou Arsobal. Bulletin de la Société de Pathologie Exotique et de ses Filiales 45 (1952), 652–680.
36. Ceccaldi, J., Nouvelle contribution au traitement de la trypanosomiase humaine par l'Arsobal ou 3854 RP. Son efficacite chez les anciens trypanoses atteints de méningo-encéphalite, resistants aux trypanocides généralement utilises. Bulletin de la Société de Pathologie Exotique et de ses Filiales 46 (1953), 95–111.
37. Cheson, B.D., Levine, A.L., Mildvan, D., Kaplan, L.D., Wolfe, P., Rios, A., Groopman, J., Gill, P., Volberding, P.A., Poiesz, B.J., Gottlieb, M., Holden, H., Volsky, D.J., Silver, S.S., Hawkins, M.J., Suramin therapy in AIDS and related disorders. Report of the US suramin working group. Journal of the American Medical Association 258 (1987), 1347–1351.
38. Chesterman, C.C., The therapeutic effect of “Bayer 205” in trypanosomiasis of the central nervous system. Transactions of the Royal Society of Tropical Medicine and Hygiene 18 (1924), 311–317.
39. Clarkson, A.B., Bienen, E.J., Bacchi, C.J., McCann, P.P., Nathan, H.C., Hutner, S.H., Sjoerdsma, A., New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. American Journal of Tropical Medicine and Hygiene 33 (1984), 1073–1077.
40. Collins, J.M., Klecker, R.W., Yarchoan, R., Lane, H.C., Fauci, A.S., Redfield, R.R., Broder, S., Myers, C.E., Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. Journal of Clinical Pharmacology 26 (1986), 22–26.
41. Collomb, H., Ayats, H., Martino, P., Lariviere, M., Les incidents et accidents du traitement de la trypanosomiase par le Mel W (Deuxieme note a propos de 40 nouvelles observations). Bulletin de la Société Medicate d'Afrique Noire de Langue Franqaise 9 (1964), 325–329.
42. Conte, J.E., Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. Journal of Infectious Diseases 163 (1991), 169–175.
43. Conte, J.E., Upton, R.A., Phelps, R.T., Wofsy, C.B., Zurlinden, E., Lin, E.T., Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. Journal of Infectious Diseases 154 (1986), 923–929.
44. Cristau, B., Placidi, M., Legait, J.P., Etude de l'excrétion de l'arsenic chez le trypanosomé traité au mélarsoprol (Arsobal). Médecine Tropicale 35 (1975), 389–401.
45. Damper, D., Patton, C.L., Pentamidine transport in Trypanosoma brucei—kinetics and specificity. Biochemical Pharmacology 25 (1976), 271–276.
46. DeGee, A.L.W., McCann, P.P., Mansfield, J.M., Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy. Journal of Parasitology 69 (1983), 818–822.
47. De Raadt, P. (1967). Reactive encephalopathy occurring as a complication during treatment of T. rhodesiense with non-arsenical drugs. East African Trypanosomiasis Research Organization Annual Report 1966, pp. 85-87.
48. De Raadt, P., Van Hoeve, K., Bailey, N.M. and Kenyanjui, E.N. (1966). Observations on the use of Berenil in the treatment of human trypanosomiasis. East African Trypanosomiasis Research Organization Annual Report 1965, pp. 60-61.
49. Docampo, R., Moreno, S.N.J., Free radical metabolism of antiparasitic agents. Federation Proceedings of the Federation of American Societies for Experimental Biology 45 (1986), 2471–2476.
50. Doua, F., Boa, F.Y., Schechter, P.J., Miézan, T.W., Diai, D., Sanon, S.R., De Raadt, P., Haegele, K.D., Sjoerdsma, A., Konian, K., Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine). Efficacy and tolerance in 14 cases in Cte d'lvoire. American Journal of Tropical Medicine and Hygiene 37 (1987), 525–533.
51. Duggan, A.J., Hutchinson, M.P., The efficacy of certain trypanocidal compounds against Trypanosoma gambiense infection in man. Transactions of the Royal Society of Tropical Medicine and Hygiene 44 (1951), 535–544.
52. Duke, H.L., On the prophylactic action of “Bayer 205” against the trypanosomes of man. Concluding observations. Lancet 230:i (1936), 463–469.
53. Dutertre, J., Labusquière, R., La thérapeutique de la trypanosomiase. Médecine Tropicale 26 (1966), 342–356.
54. East African Trypanosomiasis Research Organization, The treatment of early human trypanosomiasis cases with Berenil. Transactions of the Royal Society of Tropical Medicine and Hygiene, 69, 1975, 278.
55. Eozenou, P., Jannin, J., Ngampo, S., Carme, B., Tell, G.P., Schechter, P.J., Essai de traitement de la trypanosomiase àTrypanosoma brucei gambiense par l'eflornithine en République Populaire du Congo. Médecine Tropicale 49 (1989), 149–154.
56. Evens, F., Niemegeers, K., Packchanian, A., Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 51 (1957), 665–678.
57. Fairlamb, A.H., Novel approaches to the chemotherapy of trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84 (1990), 613–617.
58. Fairlamb, A.H., Trypanothione metabolism and rational approaches to drug design. Biochemical Society Transactions 18 (1990), 717–720.
59. Fairlamb, A.H., Bowman, I.B.R., Trypanosoma brucei suramin and other trypanocidal compounds' effects on glycerol-3-phosphate oxidase. Experimental Parasitology 43 (1977), 353–361.
60. Fairlamb, A.H., Blackburn, P., Ulrich, P., Chait, B.T., Cerami, A., Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 227 (1985), 1485–1487.
61. Fairlamb, A.H., Henderson, G.H., Cerami, A., Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proceedings of the National Academy of Sciences of the USA 86 (1989), 2607–2611.
62. Falloon, J., Kovacs, J., Hughes, W., O'Neill, D., Polls, M., Davey, R.T., Rogers, M., LaFon, S., Feuerstein, I., Lancaster, D., Land, M., Tuazon, C., Dohn, M., Greenberg, S., Lane, H.C., Masur, H., A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 325 (1991), 1534–1538.
63. Filardi, L.S., Brener, Z., Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81 (1987), 755–759.
64. Flynn, I.W., Bowman, I.B.R., Further studies on the mode of action of arsenicals on trypanosome pyruvate kinase. Transactions of the Royal Society of Tropical Medicine and Hygiene, 63, 1969, 121.
65. Fouchet, M., Gateff, C., Corticothérapie et altérations cardiovasculaires dans la trypanosomiase humaine africaine. Médecine Tropicale 28 (1968), 727–730.
66. Foulkes, J.R., An evaluation of prednisolone as a routine adjunct to the treatment of T. rhodesiense. Journal of Tropical Medicine and Hygiene 78 (1975), 72–74.
67. Fozard, J.R., The contragestational effects of ornithine decarboxylase inhibition. McCann, P.P., Pegg, A.E., Sjoerdsma, A., (eds.) Inhibition of Polyamine Metabolism. Biological Significance and Basis for new Therapies, 1987, Academic Press, Orlando, 187–202.
68. Frézil, J.L., Coulm, J., Conception actuelle de la stratégie antisommeilleuse en République Populaire du Congo. Annales de la Société Beige de Médecine Tropicale 57 (1977), 315–322.
69. Friedheim, E.A.H., Mel B in the treatment of human trypanosomiasis. American Journal of Tropical Medicine and Hygiene 29 (1949), 173–180.
70. Friedheim, E.A.H., Mel B in the treatment of tryparsamide-resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroun. American Journal of Tropical Medicine and Hygiene 31 (1951), 218–227.
71. Frommel, T.O., Balber, A.E., Flow cytofluorimetric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T.b. rhodesiense. Molecular and Biochemical Parasitology 26 (1987), 183–192.
72. Gall, D., The chemoprophylaxis of sleeping sickness with the diamidines. Annals of Tropical Medicine and Parasitology 48 (1954), 242–258.
73. Gherardi, R.K., Chariot, P., Vanderstigel, M., Malapert, D., Verroust, J., Astier, A., Brun-Buisson, C., Schaeffer, A., Organic arsenic-induced Guillain-Barré-like syndrome due to melarsoprol: a clinical electrophysiological and pathological study. Muscle and Nerve 13 (1990), 637–645.
74. Ginoux, P.Y., Lancien, P., Frézil, J.L., Bissadidi, N., Les échecs du traitement de la trypanosomiase àT. gambiense au Congo. Médecine Tropicale 44 (1984), 149–154.
75. Ginoux, P.Y., Bissadidi, N., Frézil, J.L., Accidents observés lors du traitement de la trypanosomiase au Congo. Médecine Tropicale 44 (1984), 351–355.
76. Goa, K.L., Campoli-Richards, D.M., Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinctic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33 (1987), 242–258.
77. Gorla, N.B., Ledesma, O.S., Barbieri, G.P., Larripa, I.E., Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutation Research 224 (1989), 263–267.
78. Guimaraes, J.L., Lourie, E.M., The inhibition of some pharmacological actions of pentamidine by suramin. British Journal of Pharmacology 6 (1951), 514–530.
79. Gutteridge, W., Existing chemotherapy and its limitations. British Medical Bulletin 41 (1985), 162–168.
80. Haberkorn, A., Gonnert, R., Animal experimental investigations in the activity of nifurtimox against Trypanosoma cruzi. Arzneimittel Forschung: Drug Research 22 (1972), 1570–1581.
81. Haegele, K.D., Alken, R.G., Grove, J., Schechter, P.J., Koch-Weser, J., Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clinical Pharmacology and Therapeutics 30 (1981), 210–217.
82. Haller, L., Adams, H., Merouze, F., Dago, A., Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy. American Journal of Tropical Medicine and Hygiene 35 (1986), 94–99.
83. Harding, R.D., Late results of treatment of sleeping sickness in Sierra Leone by Antrypol tryparsamide pentamidine and propamidine singly and in various combinations. Transactions of the Royal Society of Tropical Medicine and Hygiene 39 (1945), 99–124.
84. Hawking, F., Concentration of Bayer 205 (Germanin) in human blood and cerebrospinal fluid after treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 34 (1940), 37–52.
85. Hawking, F., Estimation of the concentration of melarsoprol (Mel B) and Mel W in biological fluids by bioassay with trypanosomes in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene 56 (1962), 354–363.
86. Hawking, F., Suramin: with special reference to onchocerciasis. Advances in Pharmacology and Chemotherapy 15 (1978), 289–322.
87. Hoffman, B.K., Toxicological investigations on the tolerability of nifurtimox. Arzneimittel Forschung: Drug Research 22 (1972), 1590–1603.
88. Holland, E.J., Stein, C.A., Palestine, A.G., LaRocca, R., Chan, C.C., Kuwabara, T., Myers, C.E., Thomas, R., McAtee, N., Nussenblatt, R.N., Suramin keratopathy. American Journal of Ophthalmology 106 (1988), 216–220.
89. Hunter, C.A., Jennings, F.W., Adams, J.H., Murray, M., Kennedy, P.G.E., Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet 339 (1992), 956–958.
90. Hutchinson, M., Human trypanosomiasis in South-West Ethiopa. Ethiopan Medical Journal 9 (1971), 3–69.
91. Hutchinson, M.P., Watson, H.J.C., Berenil in the treatment of Trypanosoma gambiense infection in man. Transactions of the Royal Society of Tropical Medicine and Hygiene 56 (1962), 227–230.
92. Janssens, P.G., De Muynck, A., Clinical trials with nifurtimox in African trypanosomiasis. Annales de la Société Beige de Médecine Tropicale 57 (1977), 475–479.
93. Jennings, F.W., Chemotherapy of trypanosomiasis: the potentiation of melarsoprol by concurrent difluoromethylornithine (DFMO) treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 82 (1988), 572–573.
94. Jennings, F.W., The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bulletin de la Société de Pathologie Exotique et de ses Filiales 81 (1988), 595–607.
95. Jennings, F.W., Combination chemotherapy and African trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84 (1990), 618–621.
96. Jennings, F.W., Urquhart, G.M., Murray, P.K., Miller, B.M., Treatment with suramin and 2-substituted 5-nitroimidazoles of chronic murine Trypanosoma brucei infections with central nervous system involvement. Transactions of the Royal Society of Tropical Medicine and Hygiene 77 (1983), 693–698.
97. Jennings, F.W., McNeil, P.E., Ndung'u, J.M., Murray, M., Trypanosomiasis and encephalitis: possible aetiology and treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 83 (1989), 518–519.
98. Jonchere, H., Chimioprophylaxie de la trypanosomiase humaine en Afrique Occidentale Franaise. Bulletin de la Société de Pathologie et de ses Filiales 44 (1951), 83–93.
99. Jonchère, H., Traitement par les diamidines de la phase lymphatico-sanguine de la trypanosomiase humaine en Afrique Occidentale Franaise. Bulletin de la Société de Pathologie Exotique et de ses Filiales 44 (1951), 603–625.
100. Jonchère, H., Gomer, J., Reynaud, R., Contribution à l'étude de produits à radical mélaminyl dans le traitement de la trypanosomiase humaine africaine àT. b. gambiense. Bulletin de la Société de Pathologie Exotique et de ses Filiales 46 (1953), 386–396.
101. Jones, S.K., Hall, J.E., Allen, M.A., Morrison, S.D., Ohemeng, K., Reddy, V.V., Geratz, J.D., Tidwell, R.R., Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 34 (1990), 1026–1030.
102. Kayembe, D., Wery, M., Observations sur la sensibilite aux diamidines de souches de Trypanosoma gambiense recemment isolees en République du Zaire. Annales de la Société Beige de Médecine Tropicale 52 (1972), 1–8.
103. Kazyumba, G.L., Ruppol, J.F., Tshefu, A.K., Nkanga, N., Arsenoresistance et difluoromethylornithine dans le traitement de la trypanosomiase humaine africaine. Bulletin de la Société de Pathologie Exotique et de ses Filiales 81 (1988), 591–594.
104. Keevill, A.J., Subsequent histories of six cases of Trypanosoma rhodesiense infection treated with “Bayer 205” or “Fourneau 309”. Transactions of the Royal Society of Tropical Medicine and Hygiene 28 (1934), 101–102.
105. Klatt, P., Hadju, P., Pharmacokinetic investigations on diminazene and rolitetracycline in comparison to a combination of both. Veterinary Record 99 (1976), 372–374.
106. JA Kovacs and the NIAID-Clinical Center Intramural AIDS Program, Efficacy of atovaquone in treatment of toxoplamosis in patients with AIDS. Lancet 340 (1992), 637–638.
107. LaRocca, R.V., Meer, J., Gilliatt, R.W., Stein, C.A., Cassidy, J., Myers, C.E., Dalakas, M.C., Suramin-induced polyneuropathy. Neurology 40 (1990), 954–960.
108. Le Rouzic, Traitement curatif par pentamidine et lomidine. Bulletin Médical de r'Afrique Occidentale Franaise 47 (1949), 47–51 numéro spécial.
109. Le Rouzic, Nouveaux trypanocides en expérimentation. Bulletin Médical de I'Afrique Occidentale Franaise 47 (1949), 63–72 numéro spécial.
110. Losos, G.J., Crockett, E., Toxicity of Berenil in dogs. Veterinary Record, 81, 1969, 196.
111. Lourie, E.M., The treatment of sleeping sickness in Sierra Leone. Annals of Tropical Medicine and Parasitology 36 (1942), 113–131.
112. Lumsden, W.H.R., Kimber, C.D., Strange, M., Trypanosoma brucei detection of low parasitaemias in mice by a miniature anion/excnanger centrifuga-tion technique. Transactions of the Royal Society of Tropical Medicine and Hygiene 71 (1977), 421–424.
113. Maes, L., Doua, F., Hamers, R., Elisa assay for melarsoprol. Bulletin de la Société de Pathologie Exotique et de ses Filiales 81 (1988), 557–560.
114. Marneffe, J., Observation d'un foyer de trypanosomiase rhodesiense en Urundi. Annales de la Société Beige de Médecine Tropicale 35 (1955), 357–388.
115. McCann, P.P., Bacchi, C.J., Clarkson, A.B., Bey, P., Sjoerdsma, A., Schechter, P.J., Walzer, P.D., Barlow, J.L.R., Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. American Journal of Tropical Medicine and Hygiene 35 (1986), 1153–1156.
116. Medenwald, H., Brandan, K., Schlossman, K., Quantitative determination of nifurtimox in body fluids of rat, dog and man. Arzneimittel Forschung: Drug Research 22 (1972), 1613–1617.
117. Milord, F., Pépin, J., Loko, L., Ethier, L., Mpia, B., Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340 (1992), 652–655.
118. Milord, F., Loko, L., Ethier, L., Mpia, B., Pépin, J., Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 87 (1993), 473–477.
119. Mitsuya, H., Popovic, M., Yarchoan, R., Matsushita, S., Gallo, R.C., Broder, S., Suramin protection of T-cells in vitro against infectivity and cytopathic effect of HTLV-II1. Science 226 (1984), 172–174.
120. Moens, F., De Wilde, M., Kola, N., Essai de traitement au nifurtimox de la trypanosomiase humaine africaine. Annales de la Société Beige de Médecine Tropicale 64 (1984), 37–43.
121. Monnet, A., Baylet, R., Contribution à l'étude du métabolisme du mélaminyl-4-phényl-arsénodithioglycérine en solution dans le propyléne glycol: son passage dans le liquide cephalo-rachidien. Bulletin de la Société de Pathologic Exotique el de ses Filiales 44 (1951), 754–758.
122. Monnet, A., Baylet, R., Etude de I'Slimination urinaire du 3854 RP (Mel B Friedheim — Arsobal Spécia). Médecine Tropicale 6 (1951), 893–902.
123. Nash, T.A.M., A review of the African trypanosomiasis problem. Tropical Diseases Bulletin 57 (1960), 973–1003.
124. Nathan, H.C., Bacchi, C.J., Hutner, S.H., Roscigno, D., McCann, P.P., Sjoerdsma, A., Antagonism by polyamines of the curative effects of alpha-difluoro-methylornithine on the metabolism and morphology of Trypanosoma brucei brucei infections. Biochemical Pharmacology 30 (1981), 3010–3013.
125. Neujean, G., Contribution à l'études des liquides rachidiens et céphaliques dans la maladie du sommeil àTrypanosoma gambiense. Annales de la Société Beige de Médecine Tropicale 30 (1950), 1125–1387.
126. Neujean, G. and Evens, F. (1958). Diagnostic et traitement de la maladie du sommeil áT. gambiense. Bilan de dix ans d'activité du centre de traitement de Léopoldville. Académie Royale des Sciences Coloniales: Classe des Sciences Naturelles et Médicales. Mémoires in-8, Tome VII, Fascicule 2.
127. Newton, B.A., LePage, R.W.F., Preferential inhibition of extranuclear deoxyribonucleic acid synthesis by the trypanocide Berenil. Biochemical Journal 105 (1967), 50–51.
128. Nkanga, N.G., Mutombo, L., Kazidi, K., Kazyumba, G.L., Neuropathies arsénicales après traitement de la trypanosomiase humaine au mélarsoprol. Médecine d'Afrique Noire 35 (1988), 73–76.
129. Ogada, T., Clinical Mel B resistance in Rhodesian sleeping sickness. East African Medical Journal 51 (1974), 56–59.
130. Onyango, R.J., Bailey, N.M., Okach, R.W., Mwangi, E.K. and Ogada, T. (1970). The use of Berenil for the treatment of early cases of human trypanosomiasis. East African Trypanosomiasis Research Organization Annual Report 1969, pp. 120-121.
131. Paulos, C., Paredes, J., Vasquez, I., Thambo, S., Arancibia, A., Gonzalez-Martin, G., Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. International Journal of Clinical Pharmacology Therapy and Toxicology 9 (1989), 454–457.
132. Paulson, Y.J., Oilman, T.M., Heseltine, P.N.R., Sharma, O.P., Boylen, C.T., Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with AIDS. Chest 101 (1992), 67–74.
133. Pegg, A.E., McCann, P.P., Polyamine review and function. American Journal of Physiology 243 (1982), C212–C221.
134. Pépin, J., Milord, F., African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Transactions of the Royal Society of Tropical Medicine and Hygiene 85 (1991), 222–224.
135. Pépin, J., Guern, C., Milord, F., Schechter, P.J., Difluoromethylornithine for arseno-resistant T. b. gambiense sleeping sickness. Lancet 330 (1987), 1431–1433.
136. Pépin, J., Milord, F., Guern, C., Mpia, B., Ethier, L., Mansinsa, D., Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 333 (1989), 1246–1250.
137. Pépin, J., Milord, F., Mpia, B., Meurice, F., Ethier, L., Degroof, D., Bruneel, H., An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene 83 (1989), 514–517.
138. Pépin, J., Guern, C., Milord, F., Ethier, L., Mpia, B., Schechter, P.J., Utilisation de la difluorométhylornithine dans la trypanosomiase congénitale àTrypanosoma brucei gambiense. Medecine Tropicale 49 (1989), 83–85.
139. Pépin, J., Milord, F., Guern, C., Trypanosomiase humaine africaine et normalite du liquide cephalorachidien. Médecine Tropicale 49 (1989), 29–31.
140. Pépin, J., Milord, F., Meurice, F., Ethier, L., Loko, L., Mpia, B., High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene 86 (1992), 254–256.
141. Pépin, J., Ethier, L., Kazadi, C., Milord, F., Ryder, R., The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. American Journal of Tropical Medicine and Hygiene 47 (1992), 133–140.
142. Pinedo, H.M., Van Rijswijk, R.E.N., Suramin awakes. Journal of Clinical Oncology 10 (1992), 875–877.
143. Pinto, A.R., The therapeutic effect on a group of sleeping sickness patients of a single injection of 3854 R.P. (Mel B Friedheim — Arsobal Specia). American Journal of Tropical Medicine and Hygiene 3 (1954), 464–465.
144. Raseroka, B.H., Ormerod, W.E., Suramin/metronidazole combination for African sleeping sickness. Lancet ii (1985), 784–785.
145. Raseroka, B.H., Ormerod, W.E., The trypanocidal effect of drugs in various parts of the brain. Transactions of the Royal Society of Tropical Medicine and Hygiene 80 (1986), 634–641.
146. Richet, P., Lotte, M., Foucher, G., Résultat des traitements de la trypanosomiase humaine àTrypanosoma gambiense par le Mel B. Médecine Tropicale 19 (1959), 253–265.
147. Robertson, D.H.H., The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. I-Reactions observed during treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 57 (1963), 122–133.
148. Robertson, D.H.H., The treatment of sleeping sickness (mainly due to Trypanosoma rhodesiense) with melarsoprol. II-An assessment of its curative value. Transactions of the Royal Society of Tropical Medicine and Hygiene 57 (1963), 176–183.
149. Robertson, D.H.H., A trial of Mel W in the treatment of Trypanosoma rhodesiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene 57 (1963), 274–289.
150. Ruebush, T.K., Rubin, R.H., Wolpow, E.R., Cassady, P.B., Schultz, M.G., Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. American Journal of Tropical Medicine and Hygiene 28 (1979), 184–189.
151. Ruppol, J.F., Burke, J., Follow-up des traitements contre la trypanosomiase expérimentés à Kimpangu (République du Zaire). Annales de la Société Beige de Médecine Tropicale 57 (1977), 481–494.
152. Sahai, J., Berry, A.J., Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the Acquired Immunodeficiency Syndrome: a preliminary review. Pharmacotherapy 9 (1989), 29–33.
153. Sands, M., Kron, M.A., Brown, R.B., Pentamidine: a review. Reviews of Infectious Diseases 7 (1985), 625–634.
154. Saunders, G.F.T., Holden, J.R., Hughes, M.H., Second report on the treatment of trypanosomiasis by pentamidine. Annals of Tropical Medicine and Parasitology 38 (1944), 159–168.
155. Schechter, P.J., Sjoerdsma, A., Effects on parasitic protozoa of eflornithine (DFMO): an inhibitor of polyamine biosynthesis. La Medicina Tropicale nella Cooperazione allo Svttuppo 3 (1987), 122–125.
156. Schneider, J., Traitement de la trypanosomiase humaine africaine. Bulletin of the World Health Organization 28 (1963), 763–786.
157. Scott, D., The epidemiology of Gambian sleeping sickness. Mulligan, H.W., Potts, W.H., (eds.) The African Trypanosomiases, 1970, George Allen and Unwin, London, 614–644.
158. Sina, G.C., Triolo, N., Trova, P., Clabaut, J.M., L'encéphalopathie arsénicale lors du traitement de la trypanosomiase humaine africaine àT. gambiense (à propos de 16 cas). Annales de la Société Tielge de Médecine Tropicale 57 (1977), 67–74.
159. Sina, G.C., Triolo, N., Cramet, B., Suh Bandu, M., L'adrénaline dans la prévention et le traitement des accidents de l'arsobalthérapie. A propos de 776 cas de trypanosomiase humaine africaine àT. gambiense traités dans les formations sanitaires de Fontem (R.U. du Cameroun). Médecine Tropicale 42 (1982), 531–536.
160. Smith, D.E., Davies, S., Smithson, J., Harding, I., Gazzard, E.G., Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS 6 (1992), 1489–1493.
161. Stauffert, I., Paulini, H., Steinmann, U., Sippel, H., Estler, C.J., Investigations on mutagenicity and genotoxicity of pentamidine and some related trypanocidal diamidines. Mutation Research 245 (1990), 93–98.
162. Taelman, H., Schechter, P.J., Marcelis, L., Sonnet, J., Kazyumba, G., Dasnoy, J., Haegele, K.D., Sjoerdsma, A., Wery, M., Difluoromethylornithine, an effective new treatment for Gambian trypanosomiasis. American Journal of Medicine 82 (1987), 607–614.
163. Temu, S.E., Summary of cases of human early trypanosomiasis treated with Berenil at EATRO. Transactions of the Royal Society of Tropical Medicine and Hygiene, 69, 1975, 277.
164. Tidwell, R.R., Jones, S.K., Geratz, J.D., Ohemeng, K.A., Cory, M., Hall, J.E., Analogues of l,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. Journal of Medicinal Chemistry 33 (1990), 1252–1257.
165. Tidwell, R.R., Jones, S.K., Geratz, J.D., Ohemeng, K.A., Bell, C.A., Berger, B.J., Hall, J.E., Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Annals of the New York Academy of Sciences 616 (1990), 421–441.
166. Van Hoof, L., Henrard, C., Peel, E., Pentamidine in the prevention and treatment of trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 37 (1944), 271–280.
167. Van Nieuwenhove, S. and Declerq, J. (1989). Nifurtimox therapy in late-stage arsenical-refractory gambiense sleeping sickness. Abstracts: 20th Meeting of the International Scientific Council for Trypanosomiasis Research and Control, Mombasa, April 1989.
168. Van Nieuwenhove, S., Schechter, P.J., Declercq, J., Bone, G., Burke, J., Sjoerdsma, A., Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Transactions of the Royal Society of Tropical Medicine and Hygiene 79 (1985), 692–698.
169. Veeken, H.J.G.M., Ebeling, M.C.A., Dolmans, W.M.V., Trypanosomiasis in a rural hospital in Tanzania. A retrospective study of its management and the results of treatment. Tropical and Geographical Medicine 41 (1989), 113–117.
170. Waalkes, T.P., Denham, C., DeVita, V.T., Pentamidine: clinical pharmacologic correlations in man and mice. Clinical Pharmacology and Therapeutics 11 (1970), 505–512.
171. Walzer, P.O., Kim, C.K., Foy, J., Linke, M.J., Cushion, M.T., Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 32 (1988), 896–905.
172. Wellde, B.T., Chumo, D.A., Reardon, M.J., Abinya, A., Wanyama, L., Dola, S., Mbwabi, D., Smith, D.H., Siongok, T.A., Treatment of Rhodesian sleeping sickness in Kenya. Annals of Tropical Medicine and Parasitology 83:supplement 1 (1989), 99–109.
173. Whittle, H.C., Pope, H.M., The febrile response to treatment in Gambian sleeping sickness. Annals of Tropical Medicine and Parasitology 66 (1972), 7–14.
174. Whittle, H.C., Greenwood, B.M., Bidwell, D.E., Bartlett, A., Voller, A., IgM and antibody measurement in the diagnosis and management of Gambian trypanosomiasis. American Journal of Tropical Medicine and Hygiene 26 (1977), 1129–1134.
175. WHO, 1986 Epidemiology and Control of African Trypanosomiasis. Report of a WHO Expert Committee. World Health Organization, Geneva, Technical Report Series, no. 739.
176. Williamson, J., Review of chemotherapeutic and chemoprophylactic agents. Mulligan, H.W., Potts, W.H., (eds.) The African Trypanosomiases, 1970, George Allen and Unwin, London, 126–221.
177. Yarlett, N., Goldberg, B., Nathan, H.C., Garofalo, J., Bacchi, C.J., Differential sensitivity of Trypanosoma brucei rhodesiense isolates to in vitro lysis by arsenicals. Experimental Parasitology 72 (1991), 205–215.
178. Zweygarth, E., Rottcher, D., Trypanocidal activity of 5-substituted 2-nitroimidazole compound (RO 15-0216) in mice. Tropical Medicine and Parasitology 38 (1987), 171–174.
179. Zweygarth, E., Kaminsky, R., Sayer, P.D., Van Nieuwenhove, S., Synergistic activity of 5-substituted 2-nitroimidazoles (RO 15-0216 and Benznidazole) and DL-alpha-difluoromethylornithine on Trypanosoma brucei brucei. Annales de la Société Beige de Médecine Tropicale 70 (1990), 269–279.